Literature DB >> 20485332

Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.

Eduardo H Garin1, Wei Mu, John M Arthur, Christopher J Rivard, Carlos E Araya, Michiko Shimada, Richard J Johnson.   

Abstract

Controversy exists as to whether minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) represent different diseases or are manifestations within the same disease spectrum. Urinary excretion of CD80 (also known as B7.1) is elevated in patients with MCD and hence we tested whether urinary CD80 excretion might distinguish between patients with MCD from those with FSGS. Urinary CD80 was measured in 17 patients with biopsy-proven MCD and 22 with proven FSGS using a commercially available enzyme-linked immunosorbent assay and its molecular size determined by western blot analysis. A significant increase in urinary CD80, normalized to urinary creatinine, was found in patients with MCD in relapse compared to those in remission or those with FSGS. No significant differences were seen when CD80 urinary excretion from MCD patients in remission were compared to those with FSGS. In seven of eight MCD patients in relapse, CD80 was found in glomeruli by immunohistochemical analysis of their biopsy specimen. No CD80 was found in glomeruli of two patients with FSGS and another MCD patient in remission. Thus, our study supports the hypothesis that MCD and FSGS represent two different diseases rather than a continuum of one disease. Urinary CD80 excretion may be a useful marker to differentiate between MCD and FSGS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20485332     DOI: 10.1038/ki.2010.143

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  75 in total

1.  Therapy: New data do not support use of abatacept in diabetic nephropathy.

Authors:  Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

Review 2.  Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Authors:  Hernán Trimarchi
Journal:  World J Nephrol       Date:  2013-11-06

3.  Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.

Authors:  Om P Mishra; Ravindra Kumar; Gopeshwar Narayan; Pradeep Srivastava; Abhishek Abhinay; Rajniti Prasad; Ankur Singh; Vineeta V Batra
Journal:  Pediatr Nephrol       Date:  2017-02-16       Impact factor: 3.714

Review 4.  Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Authors:  Djillali Sahali; Kelhia Sendeyo; Melanie Mangier; Vincent Audard; Shao Yu Zhang; Philippe Lang; Mario Ollero; Andre Pawlak
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

Review 5.  Minimal change disease as a modifiable podocyte paracrine disorder.

Authors:  Changli Wei; Jochen Reiser
Journal:  Nephrol Dial Transplant       Date:  2011-03-17       Impact factor: 5.992

Review 6.  [Minimal change disease and focal segmental glomerulosclerosis].

Authors:  J Müller-Deile; H Schenk; M Schiffer
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

7.  Risk of idiopathic nephrotic syndrome among children with asthma: a nationwide, population-based cohort study.

Authors:  Chang-Ching Wei; Cheng-Li Lin; Te-Chun Shen; Yu-Fen Li
Journal:  Pediatr Res       Date:  2015-04-30       Impact factor: 3.756

Review 8.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

9.  Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig-to-baboon xeno-renal transplantation - an experimental study.

Authors:  Christopher J Rivard; Tatsu Tanabe; Miguel A Lanaspa; Hironosuke Watanabe; Shunichiro Nomura; Ana Andres-Hernando; Krystle Garth; Mitsuhiro Sekijima; Takuji Ishimoto; Yuichi Ariyoshi; Gabriela E Garcia; Jigesh Shah; Boyd Lennan; Masayuki Tasaki; Thomas Pomposelli; Akira Shimizu; David H Sachs; Richard J Johnson; Kazuhiko Yamada
Journal:  Transpl Int       Date:  2018-06-05       Impact factor: 3.782

Review 10.  Minimal Change Disease.

Authors:  Marina Vivarelli; Laura Massella; Barbara Ruggiero; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.